Press Release

CHOSA Oncology AB - Bokslutskommuniké januari-december 2023

Feb 29, 2024

Sammanfattning av delårsrapport 12 månader (2023-01-01 - 2023-12-31)
• Koncernens övriga rörelseintäkter uppgick till 73 TSEK (0)
• Koncernens resultat efter finansiella poster uppgick till -23 752 TSEK (-1 167)
• Koncernens resultat per aktie uppgick till -0,37 SEK (-0,14)
• Koncernens soliditet uppgick till 89,6% (97,6)


Fjärde kvartalet (2023-10-01 – 2023-12-31)
• Koncernens övriga rörelseintäkter uppgick till 3 TSEK (0)
• Koncernens resultat efter finansiella poster uppgick till -2 630 SEK (-1 078)
• Koncernens resultat per aktie uppgick till -0,04 SEK (-0,11)


Väsentliga händelser under fjärde kvartalet 2023
• 13 oktober - CHOSA Oncology AB genomför en riktad emission om 1,55 MSEK för att
ytterligare öka verksamhetsutvecklingsaktiviteterna.
• 1 december - CHOSA Oncology AB erhåller en skattekredit på 7,8 MSEK


Väsentliga händelser efter periodens utgång
• Inga händelser

CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of LiPlaCis® and the DRP®.

About LiPlaCis® and DRP®
CHOSA is focused on late-stage clinical development of LiPlaCis® and its DRP® drug response predictor to which it has worldwide rights.  The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment.
Lung: The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that clearly increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer especially in new neoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with cisplatin-doublets.
Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.

Immunotherapy There is a new development that adds further value to our DRP. Cisplatin has often been shown to activate the immune system (making cold tumors hot), which makes tumors susceptible to PD1 inhibitors. This synergy is particularly important but not limited to the treatment of lung cancer, bladder cancer, and head and neck cancer. In the ever-growing PD1 inhibitor market, where competition is fierce, our company stands out with the ability to predict if cisplatin will provide synergy with PD1. This can give the PD1 selling companies a significant competitive advantage.

1)  Buhl et al PLOS One doi: 10.1371/journal.pone0194609
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA.
LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.